Keyphrases
Advanced Solid Tumors
100%
Gemcitabine
100%
Bortezomib
100%
Elderly Patients
100%
Phase 1 Trial
100%
Solid Tumors
50%
Thrombocytopenia
33%
Dose Level
33%
Dose-escalation Study
16%
Phase II Trial
16%
Dose Escalation
16%
Chemotherapy Regimen
16%
Maximum Tolerated Dose
16%
Dose-limiting Toxicity
16%
Anemia
16%
Advanced Stage
16%
Neutropenia
16%
Protease Inhibitors
16%
Dehydration
16%
Second Dose
16%
Partial Response
16%
Antimetabolites
16%
Lower Extremity Edema
16%
Disease Stabilization
16%
Intravenous Push
16%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
16%
Synergistic Antitumor Activity
16%
Medicine and Dentistry
Bortezomib
100%
Solid Malignant Neoplasm
100%
Gemcitabine
100%
Elderly Patient
100%
Thrombocytopenia
33%
Disease
16%
Oncology
16%
Clinical Study
16%
Anemia
16%
Neutropenia
16%
Proteasome Inhibitor
16%
Edema
16%
Antineoplastic Activity
16%
Chemotherapy Regimens
16%
Antimetabolite
16%
Isoprenaline
16%
Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
100%
Bortezomib
100%
Gemcitabine
100%
Thrombocytopenia
33%
Preclinical Study
16%
Clinical Study
16%
Antitumor Activity
16%
Chemotherapy Regimens
16%
Disease
16%
Anemia
16%
Proteasome Inhibitor
16%
Edema
16%
Maximum Tolerated Dose
16%
Isoprenaline
16%
Neutropenia
16%
Antimetabolite
16%